Scarica l'app Stockscreener
63.96
3.50%
2.16
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MRNA Giù?
Forum
Previsione
Precedente Chiudi:
$61.80
Aprire:
$63.96
Volume 24 ore:
24.04M
Relative Volume:
3.47
Capitalizzazione di mercato:
$25.38B
Reddito:
$2.23B
Utile/perdita netta:
$-3.19B
Rapporto P/E:
-7.8515
EPS:
-8.1462
Flusso di cassa netto:
$-1.60B
1 W Prestazione:
+28.85%
1M Prestazione:
+32.95%
6M Prestazione:
+106.66%
1 anno Prestazione:
+151.81%
Intervallo 1D:
$60.73
$67.74
Intervallo di 1 settimana:
$49.62
$67.74
Portata 52W:
$22.28
$67.74
Moderna Inc Stock (MRNA) Company Profile
Nome
Moderna Inc
Settore
Industria
Telefono
(617) 714-6500
Indirizzo
325 BINNEY STREET, CAMBRIDGE
Compare MRNA vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
63.96 | 25.38B | 2.23B | -3.19B | -1.60B | -8.1462 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-28 | Ripresa | Barclays | Equal Weight |
| 2026-01-07 | Ripresa | UBS | Neutral |
| 2025-12-12 | Iniziato | Jefferies | Hold |
| 2025-03-13 | Iniziato | Citigroup | Neutral |
| 2025-02-18 | Downgrade | Barclays | Overweight → Equal Weight |
| 2025-01-29 | Downgrade | Goldman | Buy → Neutral |
| 2024-12-18 | Downgrade | Argus | Buy → Hold |
| 2024-12-10 | Ripresa | BofA Securities | Underperform |
| 2024-11-19 | Iniziato | Berenberg | Hold |
| 2024-11-18 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2024-11-15 | Iniziato | Wolfe Research | Underperform |
| 2024-10-17 | Iniziato | Bernstein | Mkt Perform |
| 2024-09-13 | Downgrade | JP Morgan | Neutral → Underweight |
| 2024-09-13 | Downgrade | Jefferies | Buy → Hold |
| 2024-09-13 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-08-28 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2024-08-07 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2024-08-05 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-26 | Downgrade | HSBC Securities | Hold → Reduce |
| 2024-01-02 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2023-11-29 | Iniziato | Canaccord Genuity | Hold |
| 2023-11-03 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2023-11-02 | Downgrade | Deutsche Bank | Hold → Sell |
| 2023-08-04 | Downgrade | TD Cowen | Outperform → Market Perform |
| 2023-08-03 | Downgrade | Deutsche Bank | Buy → Hold |
| 2023-07-24 | Iniziato | William Blair | Mkt Perform |
| 2023-07-14 | Iniziato | HSBC Securities | Reduce |
| 2023-06-26 | Aggiornamento | UBS | Neutral → Buy |
| 2023-04-26 | Iniziato | Guggenheim | Neutral |
| 2023-03-13 | Aggiornamento | TD Cowen | Market Perform → Outperform |
| 2023-03-02 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-02-24 | Downgrade | SVB Securities | Market Perform → Underperform |
| 2022-12-19 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-12-14 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2022-10-21 | Aggiornamento | SVB Leerink | Underperform → Mkt Perform |
| 2022-09-08 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2022-02-01 | Aggiornamento | Redburn | Sell → Neutral |
| 2022-01-26 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2022-01-21 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2022-01-21 | Iniziato | UBS | Neutral |
| 2021-12-07 | Iniziato | Cowen | Market Perform |
| 2021-11-09 | Iniziato | Wolfe Research | Outperform |
| 2021-10-22 | Iniziato | Deutsche Bank | Sell |
| 2021-10-15 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-08-06 | Downgrade | Oppenheimer | Outperform → Perform |
| 2021-08-06 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-07-15 | Reiterato | Jefferies | Hold |
| 2021-02-01 | Downgrade | BofA Securities | Neutral → Underperform |
| 2020-12-16 | Downgrade | Jefferies | Buy → Hold |
| 2020-12-16 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-09 | Downgrade | Needham | Buy → Hold |
| 2020-11-23 | Iniziato | Wells Fargo | Equal Weight |
| 2020-11-17 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-08 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| 2020-07-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2020-07-20 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-07-13 | Iniziato | Jefferies | Buy |
| 2020-06-30 | Iniziato | Argus | Buy |
| 2020-06-08 | Iniziato | Barclays | Overweight |
| 2020-04-30 | Iniziato | BMO Capital Markets | Outperform |
| 2020-03-05 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2019-12-03 | Ripresa | BofA/Merrill | Buy |
| 2019-10-25 | Iniziato | ROTH Capital | Buy |
| 2019-04-05 | Iniziato | Chardan Capital Markets | Buy |
Mostra tutto
Moderna Inc Borsa (MRNA) Ultime notizie
Moderna, Inc. $MRNA Shares Sold by Tobam - MarketBeat
FDA panel backs first-of-its-kind flu vaccine using mRNA technology - Los Angeles Times
mRNA Patent Wars Update: Delaware Court Allows Moderna and Pfizer/BioNTech to Assert Laches in GSK Patent Infringement Cases - JD Supra
FDA panel supports first mRNA-based flu vaccine - National Desk
FDA Advisory Panel Votes 9-0 in Favor of Moderna's mRNA Flu Vaccine, Setting Stage for August Decision - BioPharm International
FDA Panel Unanimously Backs Moderna mRNA Flu Vaccine: Full Approval Expected by August - Tech Times
Moderna's Flu Vaccine Clears Key FDA Panel Vote As Advisory Committee Backs Shot 9-0 - Benzinga
MRNA Up as Influenza Vaccine Wins Unanimous FDA Advisory Panel Backing - Yahoo Finance
US FDA Panel Recommends First-Ever mRNA Flu Shot For Older Adults: All About The Moderna Vaccine - Health and Me
Moderna’s mRNA flu shot wins unanimous support at FDA adcomm in rebuke of former leadership - BioSpace
Hamilton Wealth LLC Acquires New Stake in Moderna, Inc. $MRNA - MarketBeat
Moderna flu vaccine OK’d by FDA panel - The Arkansas Democrat-Gazette
Moderna Stock On Fire: Up 34% With 5-Day Winning Streak - Trefis
First-of-its-kind flu shot may be approved for older adults - NewsNation
FDA panel gives nod to Moderna flu shot - The Hill
Moderna seeks FDA approval for its new flu shots that us MRNA technology - CBS News
FDA panel recommends mRNA flu vaccine for older adults - The Hill
Moderna (MRNA) Receives Unanimous Support for Seasonal Flu Vacci - GuruFocus
MRNA Stock Clocks Best Week In Over 4 Years On FDA Advisory Committee Endorsement For Flu Vaccine - TradingView
🔎 Under the Radar: Moderna Stock Rises on Flu-Shot Recommendation - WSJ
Moderna gains unanimous FDA panel endorsement of flu vaccine - Seeking Alpha
FDA panel backs Moderna’s flu vaccine for older adults - Investing.com
Doctor explains Moderna's candidate for first MRNA flu shot - WCVB
Moderna options trading surges to 121,257 contracts today By Investing.com - Investing.com Nigeria
Moderna (MRNA) Receives Positive Advisory Committee Vote for Inf - GuruFocus
Moderna (MRNA) Receives Positive FDA Advisory Votes for Flu Vacc - GuruFocus
FDA panel recommends Moderna’s mRNA flu shot for older adults - AOL.com
Moderna (MRNA) Shares Rise Following FDA Advisory Committee Appr - GuruFocus
Moderna flu vaccine wins unanimous support from FDA panel - BioPharma Dive
Moderna’s mRNA Flu Vaccine Wins FDA Advisory Committee Backing - Bloomberg.com
FDA Votes in Favor of Benefit-Risk Profile for Moderna’s Flu Vaccine - WSJ
FDA panel backs Moderna’s flu vaccine for older adults By Investing.com - Investing.com Canada
FDA advisers back Moderna's flu vaccine for older adults, 9-0 - Stock Titan
Moderna Secures Favorable FDA Panel Recommendation for mRNA Flu Vaccine - marketscreener.com
Stock Traders Buy High Volume of Moderna Call Options (NASDAQ:MRNA) - MarketBeat
Moderna (MRNA) Flu Vaccine Benefits Confirmed by FDA Advisers - GuruFocus
MRNA (NASDAQ) Form 144 shows 25,770-share option exercise, prior 36,759 sale - Stock Titan
Bulls Pile Into Moderna As FDA Decision Nears, Ignites 60% Surge In This ETF - Benzinga
US FDA advisers vote in favor of Moderna's flu vaccine - Reuters
Moderna options trading surges to 121,257 contracts today - Investing.com
FDA panel considers a first-of-its-kind flu vaccine using mRNA technology - KFOR
Moderna just got a signal investors can’t ignore - Yahoo Finance
Moderna's mRNA flu vaccine faces FDA advisory panel scrutiny - TradingView
Table turned, Moderna’s high-fi flu shot plays well at adcom - BioWorld News
First-of-its-kind flu vaccine could be coming as FDA panel weighs historic shot - New York Post
Moderna Extends Rally as FDA Advisory Panel Reviews Flu Vaccine Application (MRNA) - Yahoo Finance
Moderna mulls deals to rescue German BioNTech plants from closure: report - BioSpace
FDA to consider Moderna’s new mRNA flu vaccine | Morning in America - NewsNation
The Escalator: Moderna, CMI Media Group, Commonweal Ventures and more - Medical Marketing and Media
Moderna's mRNA flu vaccine backed by FDA advisers - marketscreener.com
Eversept Partners LP Invests $7.90 Million in Moderna, Inc. $MRNA - MarketBeat
Moderna Inc Azioni (MRNA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Moderna Inc Azioni (MRNA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Hoge Stephen | President |
Jun 15 '26 |
Option Exercise |
19.15 |
53,336 |
1,021,384 |
1,537,184 |
| Hoge Stephen | President |
Jun 15 '26 |
Sale |
51.37 |
53,336 |
2,739,870 |
1,483,848 |
1.38%
2.84%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):